⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14749811 | 1.00 | — | — | |
| SCHEMBL14671531 | 1.00 | — | — | |
| SCHEMBL524079 | 0.82 | — | — | |
| SCHEMBL21254015 | 0.82 | — | — | |
| SCHEMBL3114403 | 0.82 | TSHR (0.41) | — | |
| SCHEMBL24457289 | 0.82 | — | — | |
| SCHEMBL523761 | 0.82 | — | — | |
| SCHEMBL8312559 | 0.82 | TSHR (0.41) | — | |
| SCHEMBL524080 | 0.82 | — | — | |
| SCHEMBL524029 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4143179-B1 | AZETIDIN-3-YLMETHANOL DERIVATIVES AS CCR6 RECEPTOR MODULATORS FOR THE TREATMENT OF CANCER | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-10-22 | — | — | EP | claimed |
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230150976-A1 | 4-Amino Pyrimidine Compounds for the Treatment of Cancer | UNIVERSITY OF ROCHESTER (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230144581-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230011118-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED | 2023-01-12 | — | — | US | disclosed |
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
| WO-2022039199-A1 | POLY[IMINO(1-OXO-1,4-BUTANEDIYL)] COPOLYMER, RESIN COMPOSITION OF SAID COPOLYMER, AND RESIN MOLDED BODY | 株式会社クラレ | 2022-02-24 | — | — | WO | disclosed |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20070207949-A1 | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor | SCHERING CORPORATION | 2007-09-06 | — | — | US | disclosed |
| US-20070021351-A1 | Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor | SCHERING CORPORATION | 2007-01-25 | — | — | US | disclosed |
| US-20070010431-A1 | Pharmaceutical formulations and methods of treatment using the same | SCHERING CORPORATION | 2007-01-11 | — | — | US | disclosed |
| US-20070004635-A1 | Method of treating interferon non-responders using HCV protease inhibitor | SCHERING CORPORATION | 2007-01-04 | — | — | US | disclosed |
| CN-1649827-A | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | WARNER LAMBERT CO (US) | 2005-08-03 | — | — | CN | disclosed |
| US-6924377-B2 | Process for preparing highly functionalized γ-butyrolactams and γ-amino acids | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1499583-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | Warner-Lambert Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20030236415-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-25 | — | — | US | disclosed |
| US-20030225149-A1 | Process for preparing highly functionalized gamma-butyrolactams and gamma-amino acids | BLAZECKA PETER G (CA) | 2003-12-04 | — | — | US | disclosed |
| WO-2003093220-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |